Physician profile
Lori E Doyle
NPI 1558753293
$3,773.17
in general payments reported to CMS, 2019-2025
25 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $622 · 2022: $573 · 2023: $1,308 · 2024: $596 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,341 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.40 |
| Education | $236.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $698.04 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $468.74 | 2023 | Vtama |
| Abbvie INC. | $416.90 | 2021-2025 | |
| Lilly USA, LLC | $375.56 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $209.60 | 2021-2025 | |
| Ucb, INC. | $169.09 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $152.07 | 2021-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.98 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Amgen INC. | $139.38 | 2022-2025 | Otezla, Otezla, Enbrel |
| Merz North America, INC. | $128.15 | 2023 | Xeomin |
| Pfizer INC. | $116.13 | 2021-2023 | |
| Galderma Laboratories, L.P. | $102.96 | 2021-2024 | Aklief |
| Regeneron Healthcare Solutions, INC. | $99.39 | 2021-2025 | Dupixent |
| Almirall LLC | $95.45 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $90.51 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81.03 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $80.32 | 2021-2024 | Winlevi, Absorica Ld |
| Genzyme Corporation | $41.32 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $34.15 | 2025 | Zoryve |
| Epi Health, LLC | $30.47 | 2021-2022 | |
| Journey Medical Corporation | $26.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.58 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $17.39 | 2023 | Ycanth |
| Allergan, INC. | $14.73 | 2021 | |
| Organon LLC | $11.82 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.